BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

754 related articles for article (PubMed ID: 32406563)

  • 1. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance.
    Zhao S; Ma D; Xiao Y; Li XM; Ma JL; Zhang H; Xu XL; Lv H; Jiang WH; Yang WT; Jiang YZ; Zhang QY; Shao ZM
    Oncologist; 2020 Oct; 25(10):e1481-e1491. PubMed ID: 32406563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subtyping of triple-negative breast cancers: its prognostication and implications in diagnosis of breast origin.
    Hu H; Tong K; Tsang JY; Ko CW; Tam F; Loong TC; Tse GM
    ESMO Open; 2024 Apr; 9(4):102993. PubMed ID: 38613910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemistry-based molecular subtyping of triple-negative breast cancer and its prognostic significance.
    Leeha M; Kanokwiroon K; Laohawiriyakamol S; Thongsuksai P
    Pathol Oncol Res; 2023; 29():1611162. PubMed ID: 37274773
    [No Abstract]   [Full Text] [Related]  

  • 4. Feasibility of Classification of Triple Negative Breast Cancer by Immunohistochemical Surrogate Markers.
    Kim S; Moon BI; Lim W; Park S; Cho MS; Sung SH
    Clin Breast Cancer; 2018 Oct; 18(5):e1123-e1132. PubMed ID: 29754847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic characterization reveals distinct mutational landscapes and therapeutic implications between different molecular subtypes of triple-negative breast cancer.
    Li RQ; Yan L; Zhang L; Ma HX; Wang HW; Bu P; Xi YF; Lian J
    Sci Rep; 2024 May; 14(1):12386. PubMed ID: 38811720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High expression of TLR3 in triple-negative breast cancer predicts better prognosis-data from the Fudan University Shanghai Cancer Center cohort and tissue microarrays.
    Fan L; Sui XY; Jin X; Zhang WJ; Zhou P; Shao ZM
    BMC Cancer; 2023 Apr; 23(1):298. PubMed ID: 37005579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subclassifying triple-negative breast cancers and its potential clinical utility.
    Lian J; Ma HX; Xu EW; Bu P; Yun KM; Xi YF
    Virchows Arch; 2022 Jul; 481(1):13-21. PubMed ID: 35471664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial.
    Fan L; Wang ZH; Ma LX; Wu SY; Wu J; Yu KD; Sui XY; Xu Y; Liu XY; Chen L; Zhang WJ; Jin X; Xiao Q; Shui RH; Xiao Y; Wang H; Yang YS; Huang XY; Cao AY; Li JJ; Di GH; Liu GY; Yang WT; Hu X; Xia Y; Liang QN; Jiang YZ; Shao ZM
    Lancet Oncol; 2024 Feb; 25(2):184-197. PubMed ID: 38211606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer.
    Liu YR; Jiang YZ; Xu XE; Yu KD; Jin X; Hu X; Zuo WJ; Hao S; Wu J; Liu GY; Di GH; Li DQ; He XH; Hu WG; Shao ZM
    Breast Cancer Res; 2016 Mar; 18(1):33. PubMed ID: 26975198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
    Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
    Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A triple-negative breast cancer surrogate subtype classification that correlates with gene expression subtypes.
    Yoo TK; Kang J; Lee A; Chae BJ
    Breast Cancer Res Treat; 2022 Feb; 191(3):599-610. PubMed ID: 35018542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple-Negative Breast Cancer Subclassified by Immunohistochemistry: Correlation with Clinical and Pathological Outcomes in Patients Receiving Neoadjuvant Chemotherapy.
    Paula B; Crocamo S; de Sousa CAM; Valverde P; Rezende F; Abdelhay E
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Subtyping of Triple Negative Breast Cancer by Surrogate Immunohistochemistry Markers.
    Kumar S; Bal A; Das A; Bhattacharyya S; Laroiya I; Khare S; Singh G
    Appl Immunohistochem Mol Morphol; 2021 Apr; 29(4):251-257. PubMed ID: 33337632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical Profile of Triple-Negative Breast Cancers: SOX10 and AR Dual Negative Tumors Have Worse Outcomes.
    Rammal R; Goel K; Motanagh SA; Carter GJ; Clark BZ; Fine JL; Harinath L; Villatoro TM; Yu J; Bhargava R
    Mod Pathol; 2024 May; 37(7):100517. PubMed ID: 38763422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting IL-6/STAT3 signaling.
    Liu H; Yan R; Xiao Z; Huang X; Yao J; Liu J; An G; Ge Y
    Breast Cancer Res; 2023 Apr; 25(1):43. PubMed ID: 37069669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
    Coussy F; Lavigne M; de Koning L; Botty RE; Nemati F; Naguez A; Bataillon G; Ouine B; Dahmani A; Montaudon E; Painsec P; Chateau-Joubert S; Laetitia F; Larcher T; Vacher S; Chemlali W; Briaux A; Melaabi S; Salomon AV; Guinebretiere JM; Bieche I; Marangoni E
    Theranostics; 2020; 10(4):1531-1543. PubMed ID: 32042320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging features of triple-negative breast cancers according to androgen receptor status.
    Candelaria RP; Adrada BE; Wei W; Thompson AM; Santiago L; Lane DL; Huang ML; Arribas EM; Rauch GM; Symmans WF; Gilcrease MZ; Huo L; Lim B; Ueno NT; Moulder SL; Yang WT
    Eur J Radiol; 2019 May; 114():167-174. PubMed ID: 31005169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.
    Burstein MD; Tsimelzon A; Poage GM; Covington KR; Contreras A; Fuqua SA; Savage MI; Osborne CK; Hilsenbeck SG; Chang JC; Mills GB; Lau CC; Brown PH
    Clin Cancer Res; 2015 Apr; 21(7):1688-98. PubMed ID: 25208879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the Clinicopathologic Features and T-Cell Infiltration of B7-H3 and B7-H4 Expression in Triple-negative Breast Cancer Subtypes.
    Kim NI; Park MH; Cho N; Lee JS
    Appl Immunohistochem Mol Morphol; 2022 Apr; 30(4):246-256. PubMed ID: 35384874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
    Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
    BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.